Indian pharmaceutical company Strides Arcolab Ltd. (532531.BY) said Friday it has expanded its generic drugs supply agreement with Pfizer Inc. (PFE) beyond the U.S. to other developed markets and strengthened the existing drug supply agreement for the U.S. market.

Strides Arcolab will license and supply up to 38 generic cancer drugs to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan and Korea, the Indian company said in a statement.

The two companies have signed another agreement covering niche sterile injectable drugs for the U.S. market, the statement added.

The company didn't disclose any financial terms.

-By Rumman Ahmed, Dow Jones Newswires; 91-9845104173; rumman.ahmed@dowjones.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pfizer Charts.